By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Medical Answers > Can Mestinon be used to treat Postural Tachycardia Syndrome (POTS)?

Can Mestinon be used to treat Postural Tachycardia Syndrome (POTS)?

Answers by TheMediTary.Com - Last updated: 13-Jul-2023

Mestinon (pyridostigmine) has been used to treat postural tachycardia syndrome (POTS) and may improve symptoms such as a fast heart rate (tachycardia) and symptom burden (Raj et al., 2005). However, research that investigated the addition of Mestinon to standard beta-blocker treatment (propranolol or bisoprolol) found no additional advantage with the addition of Mestinon and suggested beta-blocker therapy alone to be the preferred option (Moon et al., 2018). Diarrhea is a common side effect of Mestinon that may limit its use for extended periods. The use of Mestinon for POTS is off-label (not an FDA-approved use).

Mestinon works by preventing the breakdown of acetylcholine, a nerve transmitter. A disturbance in the transmission of acetylcholine between ganglia is thought to cause the imbalance of the autonomic nervous system in POTS. Pyridostigmine increases parasympathetic nervous system activity and decreases heart rate in POTS. For more information about POTS see here.

Raj et al., 2005 performed a randomized crossover trial on 17 patients with POTS assigning them pyridostigmine (Mestinon) 30 mg orally and a placebo, on separate mornings. The patients’ heart rates were significantly lower 2 hours after pyridostigmine than after placebo (100+/-16 versus 111+/-14 bpm, P=0.001) and pyridostigmine significantly decreased the standing heart rate from baseline at 2 and 4 hours, and symptom burden at 4 hours. Blood pressure did not significantly change.

Moon et al., (2018) randomly assigned 103 POTS patients to one of 4 medical treatments (Group 1: propranolol; Group 2: bisoprolol; Group 3: propranolol+pyridostigmine (Mestinon); and Group 4: bisoprolol+pyridostigmine) for 3 months. Pyridostigmine was prescribed at a dose of 30 mg twice a day, which was maintained for 3 months. All treatments significantly improved orthostatic intolerance symptoms, symptoms of depression, and improved quality of life. Propranolol and bisoprolol demonstrated comparable therapeutic effects for POTS patients but additional pyridostigmine administration did not offer any additional benefits.

Share this Article

Featured questions

  • Can I stop taking Mestinon (pyridostigmine)?
  • What's the mechanism of action for Mestinon (pyridostigmine)?
  • Is Mestinon an Immunosuppressant?
  • If you haven't taken your mestinon for 1 week can you have withdrawals?
  • How does Mestinon help with myasthenia gravis?
  • Can these drugs be used in Thalassemia patients?
  • How does Lupron (leuprolide) work for prostate cancer?
  • What is the consideration to use nifidepine over amlodipine?
  • Hypertrophic cardiomyopathy/mechanical heart valve?
  • I have been on 400mg of tramadol a day for 20 years, decided its time to come off them
  • Cetirizine - can cetirizine be taken for long periods of time?
  • In the 1960 and 1970 what was used to treat server asthma?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch (Hydrocortisone topical)
Centrum Adult (Multivitamins and minerals)
Crovalimab
Cyltezo Prefilled Syringe (Adalimumab)
Zepbound Pen (Tirzepatide)
Mylanta One (Calcium carbonate, magnesium hydroxide, and simethicone)
Uretron Ds (Hyoscyamine, methenamine, methylene blue, phenyl salicylate, sodium biphosphate)
Medihoney Wound And Burn Dressing (Topical emollients)
Lidotrode
Libervant (Diazepam (buccal))
Moderna Covid-19 (Covid-19 (6m-11y) vaccine, moderna (2024-2025))
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)
Beqvez (Fidanacogene elaparvovec)

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by